PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242

A deeper understanding of the complex pathogenesis of multiple myeloma (MM) continues to lead to novel therapeutic approaches. Prior studies suggest that 3-phosphoinositide-dependent kinase 1 (PDK1) is expressed and active, acting as a crucial regulator of molecules that are essential for myelomagen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chunmei, Huang, Xianbo, Liu, Hui, Xiao, Feng, Wei, Jueying, You, Liangshun, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503605/
https://www.ncbi.nlm.nih.gov/pubmed/28402933
http://dx.doi.org/10.18632/oncotarget.16642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503605/
https://www.ncbi.nlm.nih.gov/pubmed/28402933
http://dx.doi.org/10.18632/oncotarget.16642

Ejemplares similares